



dandelion.com

© 2008 AGI Information Management Consultants
May be used for personal purposes only or by
libraries associated to dandelion.com network.

The Emergence and Change of Pharmacia Biotech 1959–1995

The Power of the Slow Flow and
the Drama of Great Events

Per Andersson



STOCKHOLM SCHOOL
OF ECONOMICS
THE ECONOMIC RESEARCH INSTITUTE

Contents

Foreword

PROLOGUE	1
A Strategic Reorganization and Reorientation 1989	2
Three Major Periods of Development	5
Structure of Case Narrative	9
1 THE MOVING INDUSTRIAL CONTEXT	12
Technological and Network Changes in the Pharmaceutical-Biotech Industry Network	12
The State of Biotechnology around 1989	15
A Changing Industrial Network	21
Emerging Technological Changes in the Biotech Supply Sector	24
Technological Shifts in the Pharmaceutical-Health Care Sector	31
Meanwhile: Long-Term Structural Changes in the Pharmaceutical Industry - Mergers, Concentration and Internationalization	33
2 RADICAL REORGANIZATION AND REORIENTATION 1989-1993: FOUR CONCURRENT CHANGE EPISODES	37
I. The Creation and Dismantling of Pharmacia Biosystems AB 1989-1992	39
Re-organizing Procordia	39
Merging Procordia, Provendora and Pharmacia	41
Cross-linking Processes of Change in Procordia and Volvo	42
Cross-linking Processes of Change in Kabi and Pharmacia	45
The Merger Process	49
Background: Forming Pharmacia's Strategy around "The New Biology" 1987	51
Procordia in June 1990: The Merger and Reorganization Processes Take off	53
Meanwhile: Trying to Implement the Biosystems Group of Procordia Health Care 1990-1992	55
Dispersals and Divestments 1991-1992	62
Effects on Ongoing BTG Change Processes	64
Meanwhile in the Biotechnology Group: Ongoing Processes of Marketing Change...	67

II. Regionalization - Entering a New Phase of Internationalization	69
Prelude and Forerunners to the Regionalization Project of 1990	69
Accumulating Problems of Efficiency in the New Biotechnology Group	71
The Biosystems Organization Begins to Take Shape....	74
Summer 1991: Strategic Plans for a Regionalization and a New Division of Work	78
Fall 1991: A New Brussels Office, Sub-Regionalization and Reshuffling of Internal Resources	81
Dismantling of Pharmacia Biosystems AB and New Ambiguities	84
1992: The Regionalization Project is Given a New Chance	87
Remaining Links to Former Biosystems Companies	88
A Radical Break with Established Marketing Traditions: A Comprehensive Analysis of the Customers	90
Driving the Reformulated Regionalization Process: A New View of Customer Relations	93
From Brussels to Freiburg - the European Reorganization Process Continues....	101
III. A New Motor for the Industrialization of the Biotech Operations - the Capital Rationalization and Distribution Project	103
1989: Accumulating Problems from the LKB-Pharmacia Merger	103
The Situation Analysis 1989	105
The Change Process Takes off	110
A New Organizational Structure Emerging; the Creation of Biosystems and Region Europe	112
Links to Other Change Processes; the After Sales Service Project	115
Choosing a New Transportation and Logistics Structure	116
Applying New Reports on Customer Requirements to the Logistics Project	119
1992: Summing up the Past and Heading for a New Start of the Logistics Project	121
1992: A Rapid Take-Off of the Logistics Change Process and Synergies with Other Ongoing Changes	123
IV. Striving to Implant a New View of Technical Services and Long-Term Customer Relations - the After Sales Service Project	126
1986-1989: A Stream of Disturbances in the Instrument Service Operations	126
1990: A New After Sales Service Division is Born	127
The Focal Change Areas Emerge; Defining Areas of Concern	130
Planning for a Subsidiary Meeting	131
The Copenhagen Meeting	136
Visiting the Subsidiaries	139
Breaks and Ambiguities in the After Sales Project; the New Biosystems Organization and the Regionalization Project	146
The Capital Rationalization Project; Planning for Changed Spare Part Distribution	147
The Legitimization Process Continues; Meeting with Central Support Units in Uppsala	148
The Dismantling of Pharmacia Biosystems AB and an Overview of the After Sales Service Project	150
Making Plans for Two New International Meetings	152
Revision of Meeting Plans	155
3 PRECEDING THE RADICAL REORGANIZATION: A MERGER PROCESS 1986-1989	158
The Objective of the Merger at the Outset: Creating a New, Dominating International Biotech Supplier	159
Initial Merger Strategy	161
LKB Background	162
Ongoing Processes of Change in LKB at the Time of the Merger 1986	165

	The Merger Process; Immediate Revisions of Merger Plans	167
	Presenting a New Organizational Structure	167
	The Subsidiaries Start to Merge	169
	Merging the Production Units	174
	Merging R&D Units, Product Portfolios, Stocks and Administrative Routines	180
	Focus: Merging the Service Support Operations 1986-90	186
	Merging the Subsidiaries' After Sales Units	188
	Creating a New Central Instrument Service Division	191
	1990: A New Integrated Pharmacia-LKB Biotechnology Organization Takes Shape	194
	Notes: Summary of LKB's Major Alliances, Acquisitions and Organizational Changes 1973-1986	197
4	NEW CHANGES AND A NEW EMERGING CONTINUITY 1993-1995	203
	From Three Product Companies to Four Integrated Product Divisions - Internal Adaptation to Customer Demands	205
	New Directions in the Regionalization Program	211
	A Revival for Strategic Cooperation Alliances?	212
	Towards New Technological Areas	216
	Stable Processes of Change 1993; Making the New Changes Stick	218
	1994: Continuity, Change and New Tensions to Deal with	221
	Launching BioDirect 1995	223
5	CHANGE EPISODES AND MARKETING SYSTEM EVOLUTION: IN A CONTEXT OF GREAT EVENTS (1941) 1959-1986	225
	Marketing Change Episodes and Marketing System Evolution: Building on and Breaking with a Chain of Great Events	227
	Forming the Foundations for a New Biotech Company (1941) 1959-82:	229
	Prologue 1941-1959: The Scientific Discovery of Dextran and Gel Filtration	229
	1959-1967: Emergence and Product Group Formation	234
	1967-1974: Divisionalization, Organizational Expansion and Five Important Change Events	251
	1974-1982: Subsidiary Company Formation and Technological Unification around the New Biotechnology	265
	External Expansion, Merger and Creation of a Multinational Corporation 1982-1989:	288
	1982-1989: External Expansion and Subdivisionalization	288
	The Biotech Group 1982-86: Sales Growth, Technological Changes and the Start of the External Expansion	290

6	IN THE SLOW FLOW OF A MOVING ORGANIZATIONAL CONTEXT: THE PHARMACIA CORPORATION 1911-1995	306
	Long-Term Technological Shifts: Transition and Tensions	307
	Long-Term Change and Continuity in Positions, Roles and Internal Organization	310
	Pharmacia 1911-1960: Emergence and Stable Growth of a Pharmaceutical Manufacturer	311
	Pharmacia 1960-1980: Emergence of a United, Biotechnological Corporation	316
	Pharmacia 1980-1995: Emergence of a Multinational and Diversified Pharmaceutical/Healthcare/Biotech Corporation	320
	EPILOGUE	332
	The Power of the Slow Flow	332
	The Drama of Great Events	333
	Sources	335
	Appendices	342
	1.Major Pharmacia alliances and acquisitions 1980-1990	343
	2.Major biotech suppliers emerging 1980-1995	350